{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:23:01Z","timestamp":1794370981999,"version":"4.9.0"},"reference-count":45,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate real\u2010world safety experience with aflibercept 8\u2009mg in a large case series of patients with neovascular age\u2010related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8\u2009mg. Safety data from May 2024 to October 2025 were obtained through a retrospective review of medical records by an experienced retina specialist and an additional reviewer. Symptomatic intraocular pressure (IOP) increase was defined as any symptom (e.g. pain) in conjunction with IOP\u2009&gt;\u200921\u2009mmHg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 8675 intravitreal injections of aflibercept 8\u2009mg were administered in 1429 eyes with nAMD, including 139 glaucomatous eyes. A total of 25 AEs were reported (2.88 per 1000 injections). Intraocular inflammation (IOI) was reported in 11 eyes (1.27 per 1000 injections), with 10 eyes being managed with topical dexamethasone, while one case required vitrectomy. Symptomatic IOP increase was observed in 10 cases (1.15 per 1000 injections). The occurrence of symptomatic IOP increase did not differ between glaucomatous and non\u2010glaucomatous eyes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.24). Two cases of bacterial endophthalmitis were registered. No case of retinal vasculitis or retinal vascular occlusion was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Incidence rates of symptomatic IOP increase and IOI were generally low. Despite a large glaucoma cohort, the higher incidence rate of symptomatic IOP increase in glaucomatous eyes did not reach statistical significance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/aos.70160","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:15:49Z","timestamp":1779866149000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010world insights on switching aflibercept dosage for enhanced outcomes in age\u2010related macular degeneration (\n                    <scp>RISE<\/scp>\n                    \u2010\n                    <scp>AMD<\/scp>\n                    ): Safety data"],"prefix":"10.1111","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1262-6307","authenticated-orcid":false,"given":"Mary Graciya","family":"Karunainathan","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine Aalborg University  Aalborg Denmark"},{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3555-5511","authenticated-orcid":false,"given":"Celine","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Aalborg University  Aalborg Denmark"},{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4022-0504","authenticated-orcid":false,"given":"Kaweh Daniel","family":"Zohalinejad","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3376-9364","authenticated-orcid":false,"given":"Mads Odgaard","family":"M\u00e6ng","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Aalborg University  Aalborg Denmark"},{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna W\u00fcrtz","family":"Fabrin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurr\u00f3s","family":"J\u00f3nsd\u00f3ttir","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kj\u00e6rsgaard","family":"Hassing","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Kveiborg","family":"Yde","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas Retina Consultants of America  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-0731","authenticated-orcid":false,"given":"Henrik","family":"Vorum","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-5365","authenticated-orcid":false,"given":"Yousif","family":"Subhi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Rigshospitalet  Copenhagen Denmark"},{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-5528","authenticated-orcid":false,"given":"Marie","family":"\u00d8rskov","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Aalborg University  Aalborg Denmark"},{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-7754","authenticated-orcid":false,"given":"Lasse J\u00f8rgensen","family":"Cehofski","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Aalborg University  Aalborg Denmark"},{"name":"Department of Ophthalmology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17590"},{"issue":"8","key":"e_1_2_10_3_1","first-page":"3113","article-title":"Real world experience of aflibercept 8mg at York and Scarborough teaching hospitals NHS foundation trust for neovascular age related macula degeneration (nAMD) and diabetic macular edema (DME)","volume":"66","author":"Anakwenze V.","year":"2025","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoint.2025.100124"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0969"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942\u2010025\u201000665\u20106"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2024.2370260"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/11206721251318773"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144674"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201070269\u20107"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251365391"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.024"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","unstructured":"Gartaganis P. Khamis N. Hamoud Bedan A. Driouich Z. Ashraf M.O. Abucar Osman S.et\u00a0al. (2025)A comparative assessment of intraocular pressure changes after aflibercept 8 mg and Faricimab\u2010svoa intravitreal injections in wet age\u2010related macular degeneration.Cureus[Preprint].https:\/\/doi.org\/10.7759\/cureus.88617","DOI":"10.7759\/cureus.88617"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417\u2010019\u201004354\u20107"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886\u2010024\u201003788\u2010w"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2015.29.5.325"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14608"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","unstructured":"Korobelnik J.\u2010F. Lanzetta P. Heier J.S. Leal S. Holz F.G. Clark W.L.et\u00a0al. (2025)Intravitreal aflibercept 8 mg in neovascular age\u2010related macular degeneration: 96\u2010week results from the randomized phase 3 PULSAR trial.Ophthalmology:S0161642025005329.https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022","DOI":"10.1016\/j.ophtha.2025.08.022"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16070927"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101521"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)00063\u20101"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755\u20103768.2017.03564"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S414212"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","unstructured":"Lu X. Kataoka K. Kumagai M. Nochi Y. Yamamoto A. Ko R.et\u00a0al. (2025)Comparison of intraocular pressure elevation following intravitreal injection of 70 \u03bcl aflibercept 8 mg.Japanese Journal of Ophthalmology[Preprint].https:\/\/doi.org\/10.1007\/s10384\u2010025\u201001239\u20107","DOI":"10.1007\/s10384-025-01239-7"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201091832\u2010w"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384\u2010024\u201001107\u2010w"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/life15060903"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14144900"},{"issue":"8","key":"e_1_2_10_29_1","first-page":"1863","article-title":"Endophthalmitis risk from intravitreal injections of medication in prefilled syringes vs. vials","volume":"66","author":"Papproth C.R.","year":"2025","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo\u20102024\u2010326053"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.09.024"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoint.2025.100179"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","unstructured":"Sato S. Sakurada Y. Fukuda Y. Kotoda Y.&Kashiwagi K.(2025)Recurrence of intraocular inflammation following an aflibercept 8\u2010mg injection in eyes with a history of intraocular inflammation from Faricimab: a case report.Cureus.https:\/\/doi.org\/10.7759\/cureus.86113","DOI":"10.7759\/cureus.86113"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433\u2010020\u20100853\u20109"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1897628"},{"issue":"7","key":"e_1_2_10_36_1","first-page":"217","article-title":"Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96\u2009weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg","volume":"65","author":"Stahl A.","year":"2024","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16709"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182278ab4"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231210749"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123\u2010025\u201001098\u2010y"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.008"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214\u2010109X(13)70145\u20101"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.2421"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14144821"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14141"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep39301"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.70160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.70160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.70160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:52:04Z","timestamp":1794369124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.70160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10.1111\/aos.70160"],"URL":"https:\/\/doi.org\/10.1111\/aos.70160","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"2026-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}